YY1 accelerates oral squamous cell carcinoma progression through long non-coding RNA Kcnq1ot1/microRNA-506-3p/SYPL1 axis

Yi Ding1,2†, Heng Duan3†, Jian Lin4 and Xuanxuan Zhang1*

Abstract

Objective: Ying Yang1 (YY1) has already been discussed in oral squamous cell carcinoma (OSCC), but the knowledge about its mediation on long non-coding RNA KCNQ1 overlapping transcript 1/microRNA-506-3p/synaptophysin like 1 (Kcnq1ot1/miR-506-3p/SYPL1) axis in OSCC is still in its infancy. Hence, this article aims to explain the mechanism of YY1/Kcnq1ot1/miR-506-3p/SYPL1 axis in OSCC development.

Methods: YY1, Kcnq1ot1, miR-506-3p and SYPL1 expression levels were determined in OSCC tissues. The potential relation among YY1, Kcnq1ot1, miR-506-3p and SYPL1 was explored. Cell progression was observed to figure out the actions of depleted YY1, Kcnq1ot1 and SYPL1 and restored miR-506-3p in OSCC. OSCC tumorigenic ability in mice was examined.

Results: Elevated YY1, Kcnq1ot1 and SYPL1 and reduced miR-506-3p were manifested in OSCC. YY1 promoted Kcnq1ot1 transcription and up-regulated Kcnq1ot1 expression, thereby promoting OSCC cell procession. Silencing Kcnq1ot1 or elevating miR-506-3p delayed OSCC cell progression and silencing Kcnq1ot1 impeded tumorigenic ability of OSCC cells in mice. YY1-mediated Kcnq1ot1 sponged miR-506-3p to target SYPL1.

Conclusion: YY1 promotes OSCC cell progression via up-regulating Kcnq1ot1 to sponge miR-506-3p to elevate SYPL1, guiding a novel way to treat OSCC.

Keywords: Oral squamous cell carcinoma, Ying Yang1, Long non-coding RNA KCNQ1 overlapping transcript 1, MicroRNA-506-3p, Synaptophysin like 1

Introduction

Oral squamous cell carcinoma (OSCC) arises de novo, accompanied by latent malignant lesions, including erythroplakia and leukoplakia [1]. In most cases of oral and maxillofacial cancers, OSCC stands with hostile and invasive properties [2]. Surgical resection, immunotherapy, chemotherapy and radiotherapy are inclusive in the standard treatments of OSCC [3]. Miserably, due to diagnosis in the late stage and local recurrence after surgical resection, OSCC patients often experience an unwanted survival [4]. The catastrophic disease has imposed great...
sufferings on patients, which gives an impetus to search for effective therapeutic agents.

Yin Yang 1 (YY1) has been investigated as a transcriptional factor which enhances esophageal squamous cell carcinoma (ESCC) cell proliferation [5]. Also, a liaison has been observed between overexpressed YY1 and inferior survival of tongue squamous cell carcinoma (TSCC) patients, indicating that YY1 may regulate the malignant phenotype of SCC [6]. LncRNA KCNQ1 overlapping transcript 1 (Kcnq1ot1) is the one, whose transcription can be activated by YY1 to up-regulate its own expression [7]. Kcnq1ot1 has been recently studied to induce cisplatin resistance for tongue cancer via regulation of microRNA (miR)-124-3p [8]. Moreover, Kcnq1ot1 is regarded as a promoter for tumorigenic activities of OSCC cells through modulating miR-185-5p [9], and an activator for enhancing TSCC cell proliferation and cisplatin resistance by mediating miR-211-5p [10]. The interaction network of lncRNA-miRNA is also proved between Kcnq1ot1-miR-506-3p [11]. miR-506-3p is defined as a modifier of Kcnq1ot1, which is a potential factor which enhances esophageal squamous cell carcinoma (CRC) and papillary thyroid carcinoma, and can serve as a biomarker for disease diagnosis [15, 16]. In general, YY1, Kcnq1ot1, miR-506-3p and SYPL1 have the applicable prospects in treating cancers, but the mechanism focused on their loop feedback in OSCC was rarely elaborated. Therefore, YY1/Kcnq1ot1/miR-506-3p/SYPL1 axis becomes the pivot of this study.

Methods and materials

Ethics statement
The study protocol was approved by the Ethics Committee of the Guangdong Pharmaceutical University. The written informed consent of all patients was obtained. Animal experiments were approved by the Animal Protection and Use Committee of the Guangdong Pharmaceutical University.

Study design
This study was to investigate the effect of YY1-regulated Kcnq1ot1 on the growth and development of OSCC cells through the regulation of SYPL1 expression by miR-506-3p. Clinical samples were collected and subjected to RT-qPCR to detect the expression levels of YY1, Kcnq1ot1, miR-506-3p and SYPL1. Human oral keratinocytes (HOK) and OSCC cell lines were cultured, and the expression levels of YY1, miR-506-3p, Kcnq1ot1, and SYPL1 in each cell line were detected by RT-qPCR. Through the differential expression of genes in each OSCC cell line, two target cells in this study were screened for subsequent experiments. In both target cells, MTT assay and colony formation assay were utilized for detecting cell proliferation, flow cytometry for measuring cell apoptosis, Transwell assay for determining cell migration and invasion after interference with YY1, Kcnq1ot1, miR-506-3p, and SYPL1. An OSCC mouse model was established. After treatment, the tumor volume and weight of the mice were recorded, and the tissues were stained with TUNEL to elucidate the effect of Kcnq1ot1 on OSCC in vivo.

Clinical specimen collection
From patients undergoing surgery, 98 pairs of OSCC tissues and normal tissues were obtained. None of them had received radiotherapy and chemotherapy before surgery.

Cell culture
Human oral keratinocytes (HOK) and human OSCC cell lines (Cal-27, SCC-25, SCC-9, and HN4) were collected from the American Type Culture Collection (Manassas, USA). HOK were cultivated in a HOK culture medium (ScienCell, Carlsbad, CA, USA) whereas Cal-27, SCC-25 and HN4 cells in Dulbecco’s modified Eagle medium (DMEM), and SCC-9 cells in DMEM/F12. Cells were protected against mycoplasma contamination. All of the media were supplemented with 10% fetal bovine serum (FBS; Hyclone, Israel) and 100 U/mL penicillin and streptomycin (Invitrogen, CA, USA). HOK were cultivated in a HOK culture medium (ScienCell, Carlsbad, CA, USA) whereas Cal-27, SCC-25, and SCC-9 cells in Dulbecco’s modified Eagle medium (DMEM/F12). Cells were protected against mycoplasma contamination. All of the media were supplemented with 10% fetal bovine serum (FBS; Hyclone, Israel) and 100 U/mL penicillin and streptomycin (Invitrogen, CA, USA).

Cell transfection
The coding sequence of YY1 was inserted into pcDNA3.1(+) to generate pc-YY1, with empty vector as a negative control (NC). siRNAs for YY1, Kcnq1ot1, SYPL1 and their corresponding NCs, along with miR-506-3p mimic and its NC were all obtained from GenePharma (Shanghai, China). Each transfectant was transfected into Cal-27 or SCC25 cells by Lipofectamine 3000 (Thermo Fisher Scientific, MA, USA). Successfully-transfected cells were divided into the following groups: si-NC, si-Kcnq1ot1, Vector, pcYY1, si-YY1, pcYY1+si-Kcnq1ot1, mimic-NC, mimic-miR-506-3p, si-NC and si-SYPL1 groups [18].

Reverse transcription quantitative polymerase chain reaction (RT-qPCR)
Total RNA of tissues and cells was obtained by Trizol (Invitrogen). PrimeScript RT Reagent Kit (TaKaRa, Dalian, China) and Mir-X™ miRNA First-Strand Synthesis Kit (TaKaRa) were utilized for reverse transcription of the extracted RNA into cDNA. The cDNA was then diluted
and subjected to RT-qPCR using SYBR Green Master Mix (TaKaRa) by using a CFX Real-time PCR system (Bio-Rad, Hercules, CA, USA). The primers for PCR were listed in Supplementary Table 1. Taking glyceraldehyde-3-phosphate dehydrogenase and U6 as internal controls, the gene expression was calculated by $2^{-\Delta\Delta Ct}$ [19].

**Western blot assay**

Total protein was extracted using radio-immunoprecipitation assay (RIPA) lysis buffer (Gibco, Carlsbad, CA, USA) containing phenylmethanesulfonyl fluoride (PMSF), and tested by a bicinchoninic acid kit (Sangon, Shanghai, China). Separated through sodium dodecyl sulphate polyacrylamide gel electrophoresis, the protein samples were electroblotted to polyvinylidene fluoride membranes and blocked with 5% skim milk. After that, membranes were probed with anti YY1 (1:1000; Santa Cruz Biotechnology, CA, USA) and SYPL1 (1:1000; Abcam, MA, USA) overnight, and with the corresponding secondary antibody for 2 h. Protein bands were developed by enhanced chemiluminescence (Millipore, MA, USA).

**3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay**

Cal-27 and SCC25 cells were cultivated in a culture medium on 96-well plates at $6 \times 10^3$ cells/well. MTT buffer was added into each well at post 24 h, 48 h, and 96 h cultivation. Subsequently, cells were cultivated for another 6 h to measure optical density (OD$_{570}$ nm) on a microplate reader (Thermo Fisher Scientific) [20].

**Colony formation assay**

Cal-27 and SCC25 cells were cultured for 21 d in 10% FBS-DMEM on 6-well plates (Corning, NY, USA) at 200 cells/well. Colonies fixed with methanol and stained with 0.5% crystal violet (Sigma-Aldrich, MO, USA) were counted.

**Flow cytometry**

Cell apoptosis rate was determined by eBioscience Annexin V-fluorescein isothiocyanate (FITC) Apoptosis Detection Kit (Thermo Scientific). Cal-27 or SCC25 cells after detachment were resuspended in 1 x binding buffer and reacted with propidium iodide and FITC-Annexin V. The cell apoptosis rate was evaluated on a flow cytometer (FACScan, BD Biosciences, Franklin Lakes, NJ, USA).

**Transwell assay**

Cell invasion and migration were examined by Transwell chamber (Corning) with or without matrigel (BD Biosciences). The upper side was filled with serum-free medium and added with cell suspension (200 µL) whereas the lower side contained 10% FBS-DMEM. After 24 h, with cells on the upper side wiped off, those on the lower side were fixed with 4% paraformaldehyde and stained with crystal violet buffer. Lastly, cells were photographed and quantified in 5 random fields [21].

**Chromatin immunoprecipitation (ChIP)**

A commercially kit (Beyotime, Shanghai, China) was applied for ChIP. Cells were cross-linked with 1% formaldehyde and sonicated on ice to produce 200–500 bp fragments. The chromatin was probed with anti YY1 or immunoglobulin G. The precipitated chromatin DNA was examined by RT-qPCR [22].

**RNA pull down assay**

Pre-cooled cells were incubated with RNA probe labeled with high-affinity biotin and 50 µL streptavidin magnetic beads (Thermo Fisher Scientific), and then immersed with 300 µL buffer twice. An antagonist miR-506-3p probe was regarded as a NC. Trizol was utilized for extracting total RNA to measure miR-506-3p expression by RT-qPCR.

**Dual luciferase reporter gene assay**

Kcnq1ot1 and SYPL1 3'UTR sequences containing miR-506-3p binding site or mutant binding site were synthesized by Generalbio (Anhui, China) to produce Kcnq1ot1-wilde type (WT) and SYPL1-WT or Kcnq1ot1-mutant (MUT) and SYPL1-MUT. These reporter vectors were co-transfected into Cal-27 cells with miR-506-3p mimic or mimic NC through Lipofectamine 3000 (Invitrogen) for determining luciferase activities on a luciferase reporter gene kit (Beyotime) [23].

**Subcutaneous xenograft nude mice model**

The nude mice (4–5 weeks old) were kept in a specific pathologic-free environment. To establish the subcutaneous xenograft model, nude mice were injected subcutaneously with Cal-27 or SCC25 cells stably expressing si-Kcnq1ot1 or si-NC (5 mice per group). Since that, tumor growth was monitored every 5 d when the tumor masses were identified, and tumor volume was estimated by $(\text{length} \times \text{width}^2) \times 0.52$. Mice were euthanized a month later, and the tumors were subsequently excised, photographed, with the tissues sections selected for further experiments [17].

**Transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) staining**

Tumor tissues were fixed with 10% paraformaldehyde and embedded in paraffin. Then, tissues were interacted
with the TUNEL mixture (POD, Roche) and observed under a fluorescence microscope (Olympus) to calculate the positive rate.

Statistical analysis
Data evaluation was completed on SPSS21.0 (IBM, NY, USA) and GraphPad Prism version 6.0 (GraphPad Software, San Diego). Measurement data were presented in mean ± standard deviation. The t test was employed to compare data between two groups. One-way analysis of variance (ANOVA) was indicated to evaluate data among multiple groups. Pearson test was indicated to correlation analysis. Log-rank test and Kaplan-Meier (K-M) curve were used to analyze the survival differences between the patients. Statistical significance was established with P < 0.05.

Results
Kcnq1ot1 is overexpressed in OSCC; silenced Kcnq1ot1 delays OSCC progression
Kcnq1ot1 has been proved to promote TSCC cells to proliferate [10], and it is up-regulated in tongue cancer [8]. Kcnq1ot1 expression in OSCC tissues and normal tissues (n = 98) was tested by RT-qPCR, showing a raised trend in OSCC tissues (Fig. 1A). In addition, its expression showed the same trend in OSCC cell lines (Cal-27, SCC-25, SCC-9 and HN4) versus to HOK cell line (Fig. 1B).

Kcnq1ot1 knockdown was performed in Cal27 (with highest Kcnq1ot1 expression compared with HOK cells) and in SCC25 cells (with lowest Kcnq1ot1 expression compared with HOK cells) to further survey its functional action in OSCC. Firstly, RT-qPCR proved that Kcnq1ot1 expression was effectively inhibited in Cal-27 and SCC25 cells (Fig. 1C; Supplementary Fig. 1A). Then, when detecting Cal-27 and SCC25 cell progression, the result data presented that cell viability, colony-forming ability, migration and invasion were all depressed, and apoptosis was induced upon downregulating Kcnq1ot1 (Fig. 1D-H; Supplementary Fig. 1B-F). The results hinted the repressive effects of silenced Kcnq1ot1 on OSCC cells.

YY1 promotes Kcnq1ot1 transcription and elevates Kcnq1ot1 expression to promote OSCC progression
It has been confirmed that the abnormally expressed lncRNA is stimulated by transcriptional activation, which might be affected by transcription factors [24]. Meanwhile, YY1 activated LINC00673 to reinforce breast cancer cell proliferation through the miR-515-5p/
microtubule affinity regulating kinase/Hippo signaling pathway [22]. YY1 expression was firstly examined in OSCC tissues and normal tissues and the outcome displayed that YY1 was overexpressed in OSCC tissues (Fig. 2A). To proceed, whether YY1 regulated Kcnq1ot1 in OSCC was explored via ChIP assay. The results reported that anti-YY1 pulled down Kcnq1ot1 promoter (Fig. 2B). Moreover, in Cal-27 cells expressing up-regulated YY1, Kcnq1ot1 expression was raised, and vice versa (Fig. 2C). Also, in OSCC tissues, there was a positive correlation between Kcnq1ot1 and YY1 expression (Fig. 2D).

Subsequently, the mechanism that YY1 mediated Kcnq1ot1 in OSCC was investigated. It was revealed that transfection with pc-YY1 could increase YY1 and Kcnq1ot1 expression in Cal27 cells, further transfection with si-Kcnq1ot1 could reduced Kcnq1ot1 expression (Fig. 2E, F).

Through in vitro experiments, it was measured that overexpressed YY1-induced enhancements of Cal-27 cell viability, colony-forming, invasion and migration abilities and impairment of apoptosis were offset by knockdown of Kcnq1ot1 (Fig. 2G-K). In short, YY1 promoted Kcnq1ot1 transcription and up-regulated its expression, thereby promoting OSCC development.

Knocking down Kcnq1ot1 suppresses tumorigenic ability of OSCC cells in mice
As to the issue that how Kcnq1ot1 acted in OSCC in vivo, Cal-27 cells stably expressing sh-Kcnq1ot1 or sh-NC were injected into mice. The tumors expressing with sh-Kcnq1ot1 showed reduced volume and weight (Fig. 3A-C), decreased Kcnq1ot1 expression (Fig. 3D) and enhanced cell apoptosis (Fig. 3E). Taken together, knockdown of Kcnq1ot1 suppressed OSCC tumor growth.
miR-506-3p was a potential therapeutic target in cancer cells, as evidenced by its suppressive effects on nasopharyngeal carcinoma, osteosarcoma and gliomas [25–27]. In addition to protein-coding genes, miRNAs can target lncRNAs. Among candidate targets of miR-506-3p predicted by the starBase website, we found the binding sequences between miR-506-3p and Kcnq1ot1 (Fig. 4A). Furthermore, dual luciferase reporter gene assay revealed that miR-506-3p mimic had impaired effects on the luciferase activity of WT-Kcnq1ot1 but not on that of MUT-Kcnq1ot1 in Cal-27 cells (Fig. 4B). RNA pull down assay detected that in Cal-27 cells, miR-506-3p was enriched in the Bio-Kcnq1ot1-WT group but not in the Bio-Kcnq1ot1-MUT group (Fig. 4C). RT-qPCR outlined that miR-506-3p expression was heightened upon YY1 or Kcnq1ot1 knockdown (Fig. 4D). YY1 and Kcnq1ot1 expression in OSCC tissues were found to be negatively correlated with miR-506-3p expression (Fig. 4E, F). It could be summarized that YY1-mediated Kcnq1ot1 competitively bound to miR-506-3p to regulate miR-506-3p expression.

Elevating miR-506-3p restrains tumorigenesis of OSCC in mice

RT-qPCR examined miR-506-3p expression in clinical tissues in OSCC. Revealed by the experimental results, miR-506-3p expression was suppressed in OSCC tissues (Fig. 5A). Consistently, miR-506-3p expression in OSCC cells was lower than that in HOK cells (Fig. 5B). Through the 5-year prognosis statistics of patients with OSCC, it was found that low expression of miR-506-3p was related to a poor prognosis of patients (Fig. 5C). In addition, miR-506-3p expression was related to the tumor clinical stage and lymph node metastasis, but not to gender, age, and tumor differentiation (Supplementary Table 2).

Up-regulated miR-506-3p was introduced into Cal-27 cells to further clarify its function in OSCC (Fig. 5D). The findings highlighted that restored miR-506-3p impaired OSCC cell progression (Fig. 5E-I). We performed the same experiments in SCC25 cells, and the results showed that the trend was consistent with Cal27 cells (Supplementary Fig. 2A-F).

Kcnq1ot1 regulates miR-506-3p to mediate SYPL1 expression

miR-506-3p could regulate target genes in cancer cells [27]. It was assumed that miR-506-3p repressed OSCC progression by binding to its target gene. SYPL1, a member of SYP family of proteins, is originally reported to be a protein associated with neuroendocrine-specific synaptophysin, and recently discovered in non-nerve tissues [28]. SYPL1 was predicted as the target gene of miR-506-3p to participate in OSCC. On the bioinformatics website, it was disclosed that SYPL1 may be a potential target of miR-506-3p (Fig. 6A). Next, dual luciferase report gene assay validated (Fig. 6B) that
miR-506-3p mimic undermined the luciferase activity of SYPL1-WT, evidencing the targeting relationship between these two.

Kcnq1ot1 competitively binds to miR-506-3p

To delineate the regulatory mechanism among Kcnq1ot1, SYPL1 and miR-146a-5p, si-YY1, si-Kcnq1ot1 and mimic-miR-506-3p was transfected in Cal-27 cells, respectively. The data showed that SYPL1 expression was always repressed after transfection with the above plasmids. Transfection with pc-YY1 could augment SYPL1 expression in cells (Fig. 6C, D). In OSCC tissues, SYPL1 expression was positively correlated with YY1 and Kcnq1ot1 expression, and negatively with miR-506-3p expression (Fig. 6E-G).

Inhibiting SYPL1 restricts OSCC progression

Overexpressed SYPL1 was closely tied up with malignant clinicopathological features in hepatocellular carcinoma [28]. To explore the effects of SYPL1 on OSCC, its expression in OSCC tissues and normal tissues was determined by RT-qPCR. The results demonstrated that SYPL1 expression was augmented in OSCC tissues (Fig. 7A).

Transfection with si-SYPL1 was conducted in Cal-27 cells to down-regulate SYPL1 expression in OSCC (Fig. 7B, C). As a result of SYPL1 inhibition, the malignant activities of OSCC cells were disrupted (Fig. 7D-H). We performed the same experiments in SCC25 cells and found that inhibiting SYPL1 repressed the growth of SCC25 cells (Supplementary Fig. 3A-F).
Discussion

OSCC is defined as one of the tumors in the oral epithelium [29]. Abnormalities in YY1, Kcnq1ot1, miR-506-3p, and SYPL1 have been manifested in cancer progression. Given that, it is speculated that targeting YY1/Kcnq1ot1/miR-506-3p/SYPL1 axis may possess the potential to treat OSCC. For verifying the speculation, this research was launched to obtain the major result that YY1-mediated Kcnq1ot1 depresses miR-506-3p to up-regulate SYPL1, thereafter to facilitate OSCC development.

To start, YY1 and Kcnq1ot1 expression in OSCC was determined, along with their interactions in OSCC cell progression. The experimental results presented that YY1 and Kcnq1ot1 were both overexpressed in OSCC, and YY1 activated Kcnq1ot1 transcription to elevate Kcnq1ot1 expression. Functionally evidenced by various assays, YY1 or Kcnq1ot1 overexpression gave the opportunity for OSCC cells to act offensively while Kcnq1ot1 knockdown disrupted the cellular fate. Moreover, Kcnq1ot1 knockdown performed in vivo also exhibited the same inhibitory effects on tumorigenic ability of OSCC cells in vivo. Impressively, a novel study has mentioned that YY1 expression is raised in oral cancer, facilitating proliferation, angiogenesis and metastasis of oral cancer cells [30]. Moreover, another article has reported YY1 knockdown sensitizes TSCC cells to ionizing radiation [6]. In head and neck squamous cell carcinoma, YY1 expression goes toward an up-regulation while YY1 depletion strengthens cell apoptosis and interferes cell proliferation, migration and invasion [31]. Furthermore, overexpressed YY1 in ESCC has been revealed to promote ESCC cell invasion and migration, as well as metastatic behaviors [32, 33]. It is academically reflected that transcriptional activation of Kcnq1ot1 is stimulated by YY1 [7]. Cisplatin-resistant tongue cancer tissues and cells witness the enhancement of Kcnq1ot1 and its silencing is attributable to restricted pro-proliferative, pro-migrating, pro-invasive properties of malignant cells [8]. Specifically, Kcnq1ot1 expression reaches a high level in OSCC tissues and cells and depleting it muffles invasion and induces apoptosis of OSCC cells [9]. Observed in another work, incremental Kcnq1ot1 is the activator for TSCC proliferation while reduced Kcnq1ot1 functions reversely [10].

Next, miR-506-3p was predicted and verified to interact with Kcnq1ot1. As manifested, miR-506-3p was down-regulated in OSCC. By up-regulating miR-506-3p, the biological behaviors of OSCC cells were disturbed. An existed literature has shown Kcnq1ot1 targeting miR-506-3p [11]. miR-506 expression is apt
to decline in laryngeal squamous cell carcinoma and restored miR-506 curbs cell proliferation, migration and invasion [34]. Besides that, in esophageal cancer, miR-506 also shows a reduced level while its enforced expression destroys cell proliferation [35]. In light of its presentation in OSCC, miR-506 is down-regulated, whereas miR-506 up-regulation depresses proliferation, migration and invasion of OSCC cells [14]. Previously discussed, inhibited miR-506-3p expression is noticeable in ovarian cancer and prostate cancer, and accumulated miR-506-3p is conducive in undermining cell viability and triggering apoptosis [36, 37].
Subsequently, SYPL1 was validated to be targeted by miR-506-3p, and its expression was negatively connected with miR-506-3p expression but positively with YY1 and Kcnq1ot1 expression. Followed by that, SYPL1 down-regulation in OSCC cells was found to obstruct cells to behave aggressively. The targeting connection between miR-506-3p and SYPL1 has been seldom identified previously. Clinically, SYPL1 expression is characterized with an increase in hepatocellular carcinoma, unfortunately resulting in miserable overall survival and disease-free survival [28]. Consistent the study finding in the present work, another research focused on CRC has reported the overexpressed SYPL1 [15]. From all of the listed reports, it is easy to abstract that the manifestations of these four factors (YY1, Kcnq1ot1, miR-506-3p and SYPL1) in the malignant phenotypes of cancers are consonant with the findings in the present work.

**Conclusion**

To sum up, it is delineated in this article that YY1-mediated Kcnq1ot1/miR-506-3p/SYPL1 axis promotes OSCC cell progression. Much scientific and scrutinized studies are at wanting for further confirmation and extension of the obtained results in a larger cohort.

**Supplementary Information**

The online version contains supplementary material available at https://doi.org/10.1186/s13048-022-01000-5.

**Additional file 1: Supplementary Figure 1.** Downregulation of Kcnq1ot1 inhibits the progression of SCC25 cells. A. RT-qPCR for detecting Kcnq1ot1 expression after down-regulating Kcnq1ot1; B-C. MTT assay and colony formation assay for determining cell proliferation after down-regulating Kcnq1ot1; D. Flow cytometry for measuring cell apoptosis after down-regulating Kcnq1ot1; E-F. Transwell assay for testing cell migration and invasion after down-regulating SYPL1; * P < 0.05 compared with the si-NC group; Measurement data were expressed as mean ± standard deviation.

**Additional file 2: Supplementary Figure 2.** Elevating miR-506-3p restrains the functions of SCC25 cells. A. RT-qPCR for determining miR-506-3p expression after up-regulating miR-506-3p; B-C. MTT assay and colony formation assay for testing cell proliferation after up-regulating miR-506-3p; D. Flow cytometry for measuring cell apoptosis after up-regulating miR-506-3p; E-F. Transwell assay for the determination of cell migration and invasion after up-regulating miR-506-3p; * P < 0.05 compared with the mimic-NC group; Measurement data were expressed as mean ± standard deviation.

**Additional file 3: Supplementary Figure 3.** Inhibiting SYPL1 restricts the development of SCC25 cells. A. RT-qPCR was performed to test SYPL1 expression in OSCC tissues and normal tissues, n = 98; B-C. RT-qPCR and Western blot assay were conducted to determine SYPL1 expression after down-regulating SYPL1; D-E. MTT assay and colony formation assay were carried out to detect cell proliferation after down-regulating SYPL1; F. Flow cytometry was utilized to measure cell apoptosis after down-regulating SYPL1; G-H Transwell assay was carried out to detect cell migration and invasion after down-regulating SYPL1; ^ P < 0.05 compared with the si-NC group; Measurement data were expressed as mean ± standard deviation.

**Additional file 4: Supplementary Table 1.** Primer sequences for genes in this study. Supplementary Table 2. The correlation between miR-506-3p expression and clinicopathological characteristics of patients with oral squamous cell carcinoma.
Authors’ contributions
Xuanxuan Zhang finished study design, Yi Ding, Heng Duan, Jian Lin finished experimental studies, Yi Ding, Heng Duan, Jian Lin finished data analysis, Yi Ding, Heng Duan finished manuscript editing. All authors read and approved the final manuscript.

Funding
This study was financially supported by the National Natural Science Foundation of China (82104241 to X.Z) and the Project of Administration of Traditional Chinese Medicine of Guangdong Province of China (20202106 to YD), the Medical Scientific Research Foundation of Guangdong Province, China (A2020368 to X.Z and B2019123 to H.D), the Science and Technology Program of Guangzhou, China (202102021033 to X.Z), and the Internal Fund of Southern Medical University (PY2018090 to H.D).

Availability of data and materials
The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

Declarations

Ethics approval and consent to participate
The study protocol was approved by the Ethics Committee of the Guangdong Pharmaceutical University. The written informed consent of all patients was obtained. Animal experiments were approved by the Animal Protection and Use Committee of the Guangdong Pharmaceutical University.

Consent for publication
Patients signed informed consent regarding publishing their data and photographs.

Competing of interests
The authors have no conflicts of interest to declare that are relevant to the content of this article.

Author details
1 Center for Drug Research and Development, Guangzhou Key Laboratory of Construction and Application of New Drug Screening Model Systems, Key Laboratory of New Drug Discovery and Evaluation of Ordinary Universities of Guangdong Province, Guangdong Pharmaceutical University, No. 280, Waihuan East Road, Guangzhou 510006, Guangdong, China. 2 School of Life Sciences and Biopharmaceutics, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China. Department of Pharmacy, Stomatological Hospital, Southern Medical University, Guangzhou 510280, Guangdong, China. 3 The Seventh Affiliated Hospital, Sun Yat-Sen University, Shenzhen 518107, Guangdong, China.

Received: 18 October 2021  Accepted: 16 May 2022
Published online: 01 July 2022

References
1. Behl I, Calado G, Vishwakarma A, Flint S, Galvin S, Healy CM, et al. Raman microspectroscopic study for the detection of oral field carcinoma using brush biopsy samples. J Biophotonics. 2020;13(10):e20200131.
2. Yu L, Yang Z, Liu Y, Liu F, Sheng W, Shao W, et al. Identification of SPRR3 as a novel diagnostic/prognostic biomarker for oral squamous cell carcinoma via RNA sequencing and bioinformatic analyses. PeerJ. 2020;8:e9393.
3. Wunschel M, Neumeier M, Utpatel K, Reichert TE, Ettl T, Spanier G. Staging more important than grading? Evaluation of malignancy grading, depth of invasion, and resection margins in oral squamous cell carcinoma. Clin Oral Investig. 2021;25(3):1169–82.
4. Song X, Yang X, Narayanan R, Shankar V, Ethersj S, Wang X, et al. Oral squamous cell carcinoma diagnosed from saliva metabolic profiling. Proc Natl Acad Sci U S A. 2020;117(28):16167–73.
5. Li Y, Li T, Yang Y, Kang W, Dong S, Cheng S. YY1-induced upregulation of FOXP4-A51 and FOXP4 promote the proliferation of esophageal squamous cell carcinoma cells. Cell Biol Int. 2020;44(7):1447–57.
6. Zhao L, Li R, Qu J, Yue J, Bu J, Cao Y, Yuan RT. YY1-mediated PTEF2 phosphorylation antagonizes IR-induced DNA repair contributing to tongue squamous cell carcinoma radiosensitization. Mol Cell Probes. 2020;53:101577.
7. Chen C, Kong B, Liu Y, Xiong L, Shuai W, Wang G, et al. YY1-induced upregulation of IncRNA KCNQ1OT1 regulates angiogenesis II-induced atrial fibrillation by modulating miR-384/bCACA1/4 axis. Biochem Biophys Res Commun. 2018;505(1):134–40.
8. Qiao CY, Qiao TY, Jin H, Liu LL, Zheng MD, Wang ZL. LncRNA KCNQ1OT1 contributes to the cisplatin resistance of tongue cancer through the KCNQ1OT1/miR-124-3p/TRIM14 axis. Eur Rev Med Pharmacol Sci. 2020;24(1):200–12.
9. Bao Q, Xiao L, Li R, Ding N. KCNQ1OT1 promotes migration and inhibits apoptosis by modulating miR-185-5p/Regl4 in oral squamous cell carcinoma. Dev Growth Differ. 2019;61(9):466–74.
10. Zhang S, Ma H, Zhang D, Xie S, Wang W, Li Q, et al. LncRNA KCNQ1OT1 regulates proliferation and cisplatin resistance in tongue cancer via miR-211-5p mediated Erzin/Avr/Sc signaling. Cell Death Dis. 2018;9(7):742.
11. Zhu B, Cheng X, Jiang Y, Cheng M, Chen L, Bao J, et al. Silencing of KCNQ1OT1 decreases oxidative stress and pyroptosis of renal tubular epithelial cells. Cells Metab Syndr Obes. 2020;13:365–75.
12. Wang L, Zhang Z, Yu X, Huang X, Liu Z, Chai Y, et al. Unbalanced YAP/ SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma. Oncogene. 2019;38(12):2042–55.
13. Ghifari M, Asadi M, Shanaiheebandi B, Bornehdeli S, Sadeghzadeh M, Mohammad Reza Khani H, et al. Aberrant expression of miR-103, miR-184, miR-378, miR-497 and miR-506 in tumor tissue from patients with oral squamous cell carcinoma regulates the clinical picture of the patients. Asian Pac J Cancer Prev. 2020;21(5):1311–5.
14. Deng L, Liu H. MiCroRNA-506 suppresses growth and metastasis of oral squamous cell carcinoma via targeting TAGAT3. Int J Clin Exp Med. 2015;8(2):1862–70.
15. Liu L, He Q, Li Y, Zhang B, Sun X, Shan J, et al. Serum SYPL1 is a promising diagnostic biomarker for colorectal cancer. Clin Chim Acta. 2020;509:36–42.
16. Yang C, Wang Y. Identification of differentiated functional modules in papillary thyroid carcinoma by analyzing differential networks. J Cancer Res Ther. 2018;14(Supplement):5969–74.
17. Peng GS, Cheng YN, Zhang WB, Fan H, Mao QH, Xu P. circRNA_000114 suppresses oral squamous cell carcinoma growth and metastasis by targeting miR-31 to inhibit Hippo signaling pathway. Cell Death Dis. 2020;11(2):112.
18. Qian S, Wang W, Li M. Transcriptional factor Yin Yang 1 facilitates migration and invasion in non-small cell lung cancer through upregulation of HMGA2 via sponging miR-506-3p. Cancer Cell Int. 2020;20:160.
19. Guan H, Liang W, Xie Z, Li H, Liu J, Liu L, et al. Down-regulation of miR-144 promotes thyroid cancer cell invasion by targeting ZEB1 and ZEB2. Endocrine. 2015;48(3):1291–303.
20. Huang S, Wang G, Gao Y, Zhao C, Li X, Zhang F, et al. Lnc-SNHG1 Activates miR-183-5p to induce apoptosis in papillary thyroid carcinoma by analyzing differential networks. J Cancer Res Ther. 2018;14(Supplement):5969–74.
21. Wang H, Wang G, Gao Y, Zhao C, Li X, Zhang F, et al. LncRNA KCNQ1OT1 regulates the clinical picture of the patients. Asian Pac J Cancer Prev. 2020;21(5):1311–5.
22. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25(4):402–8.
23. Guan H, Wang G, Gao Y, Zhao C, Li X, Zhang F, et al. LncRNA KCNQ1OT1 regulates the clinical picture of the patients. Asian Pac J Cancer Prev. 2020;21(5):1311–5.
24. Dai AK, McCarthy R, Allerton K, Aldemir KC, Patel LR, et al. Lnc-PRESS1 is a p33-regulated lncRNA that safeguards pluripotency by disrupting SIRT6-mediated de-acetylation of histone H3K56. Mol Cell. 2016;64(5):967–81.
25. Liang TS, Zheng YJ, Wang J, Zhao JY, Yang DK, Liu ZS. MicroRNA-506 inhibits tumor growth and metastasis in nasopharyngeal carcinoma through the inactivation of the Wnt/beta-catenin signaling pathway by down-regulating LHx2. J Exp Clin Cancer Res. 2019;38(1):97.

26. Jiashi W, Chuang Q, Zhenjun Z, Guangbin W, Bin L, Ming H. MicroRNA-506-3p inhibits osteosarcoma cell proliferation and metastasis by suppressing RAB3D expression. Aging (Albany NY). 2018;10(6):1294–305.

27. Li H, Li T, Huang D, Zhang P. Long noncoding RNA SNHG17 induces YY1 to facilitate glioma progression through targeting miR-506-3p/CTNNB1 axis to activate Wnt/beta-catenin signaling pathway. Cancer Cell Int. 2020;20:29.

28. Chen DH, Wu QW, Li XD, Wang SJ, Zhang ZM. SYPL1 overexpression predicts poor prognosis of hepatocellular carcinoma and associates with epithelial-mesenchymal transition. Oncol Rep. 2017;38(3):1533–42.

29. Wu HT, Chen WT, Li GW, Shen JX, Ye QQ, Zhang ML, et al. Analysis of the differentially expressed genes induced by cisplatin resistance in oral squamous cell carcinomas and their interaction. Front Genet. 2019;10:1328.

30. Behera AK, Kumar M, Sharmugam MK, Bhattacharya A, Rao VJ, Bhat A, et al. Functional interplay between YY1 and CARM1 promotes oral carcinogenesis. Oncotarget. 2019;10(38):3709–24.

31. Zhao L, Li R, Gan YH. Knockdown of Yin Yang 1 enhances anticancer effects of cisplatin through protein phosphatase 2A-mediated T308 dephosphorylation of AKT. Cell Death Dis. 2018;9(7):747.

32. Nie J, Ge X, Geng Y, Cao H, Zhu W, Jiao Y, et al. miR-34a induces the migration and invasion of esophageal squamous cell carcinoma by targeting Yin Yang-1. Oncoz Rep. 2015;34(1):311–7.

33. Luo J, Jiang X, Cao L, Dai K, Zhang S, Ge X, et al. Expression of YY1 correlates with progression and metastasis in esophageal squamous cell carcinomas. Onco Targets Ther. 2014;7:1753–9.

34. Gao C, Hu S. miR-506 is a YAP1-dependent tumor suppressor in laryngeal squamous cell carcinoma. Cancer Biol Ther. 2019;20(6):826–36.

35. Yao WJ, Wang YL, Lu JG, Guo L, Qi B, Chen ZJ. MicroRNA-506 inhibits esophageal cancer cell proliferation via targeting CREB1. Int J Clin Exp Pathol. 2015;8(9):10868–74.

36. Xia X, Yu Y, Ye F, Peng GY, Li Y, Zhou XM. MicroRNA-506-3p inhibits proliferation and promotes apoptosis in ovarian cancer cell via targeting SIRT1/AKT/FOXO3a signaling pathway. Neoplasma. 2020;67(2):344–53.

37. Hu CY, You P, Zhang J, Zhang H, Jiang N. MiR-506-3p acts as a novel tumor suppressor in prostate cancer through targeting GALNT4. Eur Rev Med Pharmacol Sci. 2019;23(12):5133–8.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.